Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Rating of “Hold” from Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received an average rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $5.72.

A number of equities analysts have commented on the company. Barclays restated an “underweight” rating and issued a $4.00 target price on shares of Definitive Healthcare in a research note on Monday, January 13th. Stephens assumed coverage on shares of Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th.

Insider Transactions at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the sale, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. The trade was a 9.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.84% of the stock is owned by insiders.

Institutional Trading of Definitive Healthcare

Hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its stake in shares of Definitive Healthcare by 17.0% in the second quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock valued at $125,000 after buying an additional 3,332 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Definitive Healthcare by 20.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company’s stock worth $85,000 after acquiring an additional 3,496 shares during the last quarter. Principal Financial Group Inc. increased its position in Definitive Healthcare by 9.7% in the 4th quarter. Principal Financial Group Inc. now owns 43,960 shares of the company’s stock valued at $181,000 after acquiring an additional 3,874 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Definitive Healthcare by 5.2% in the fourth quarter. Rhumbline Advisers now owns 81,316 shares of the company’s stock worth $334,000 after acquiring an additional 4,034 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Definitive Healthcare by 18.1% during the fourth quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company’s stock worth $120,000 after purchasing an additional 4,500 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Stock Performance

Shares of DH opened at $5.55 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. Definitive Healthcare has a 12-month low of $3.19 and a 12-month high of $10.62. The business’s fifty day moving average price is $4.54 and its 200 day moving average price is $4.40. The stock has a market capitalization of $641.14 million, a PE ratio of -1.79, a price-to-earnings-growth ratio of 3.94 and a beta of 1.45.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.